anti-CD20 mAb CIPEX/bio-better (Cilian)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-CD20 mAb CIPEX/bio-better (Cilian)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionB-lymphocyte antigen CD20 inhibitors
TargetsB-lymphocyte antigen CD20
Therapy Area/Indications +[1]  N/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCilian AG
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCilian AG
Active IndicationsN/A
Inactive Indications +[1]  N/A

Other Information

ATC CodeN/A
Related LinksN/A